

Contents

Highlights of This Issue 3853

SPECIAL FEATURES

CCR Translations

- 3855 **Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need**
Mrinal M. Gounder and David R. Spriggs
See article p. 4110

Molecular Pathways

- 3858 **Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target?**
Michael C. Haffner, Angelo M. De Marzo, Alan K. Meeker, William G. Nelson, and Srinivasan Yegnasubramanian

CCR Focus

- 3866 **Prostate Cancer: Score One for Validated Targets**
Susan E. Bates
- 3867 **Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients**
Gerhardt Attard and Johann S. de Bono
- 3876 **Targeting Continued Androgen Receptor Signaling in Prostate Cancer**
Christophe Massard and Karim Fizazi
- 3884 **Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research**
James L. Gulley and Charles G. Drake
- 3892 **Overcoming Chemotherapy Resistance in Prostate Cancer**
Ravi A. Madan, Sumanta Kumar Pal, Oliver Sartor, and William L. Dahut
- 3903 **Circulating Tumor Cells as Biomarkers in Prostate Cancer**
Daniel C. Danila, Martin Fleisher, and Howard I. Scher

Review

- 3913 **Pathogenesis and Consequences of Uniparental Disomy in Cancer**
Hideki Makishima and Jaroslaw P. Maciejewski

HUMAN CANCER BIOLOGY

- 3924 **Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients**
Rohit Mehra, Chandan Kumar-Sinha, Sunita Shankar, Robert J. Lonigro, Xiaojun Jing, Neena E. Philips, Javed Siddiqui, Bo Han, Xuhong Cao, David C. Smith, Rajal B. Shah, Arul M. Chinnaiyan, and Kenneth J. Pienta
- 3933 **KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites**
Katarina Omholt, Eva Grafström, Lena Kanter-Lewensohn, Johan Hansson, and Boel K. Ragnarsson-Olding
- 3943 **Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors**
Keila E. Torres, Quan-Sheng Zhu, Katelynn Bill, Gonzalo Lopez, Markus P. Ghadimi, Xianbiao Xie, Eric D. Young, Juehui Liu, Theresa Nguyen, Svetlana Bolshakov, Roman Belousov, Suizhau Wang, Guy Lahat, Jun Liu, Belinda Hernandez, Alexander J. Lazar, and Dina Lev

CANCER THERAPY: PRECLINICAL

- 3956 **Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters**
Sílvia Xargay-Torrent, Mónica López-Guerra, Ifigènia Saborit-Villarroya, Laia Rosich, Elias Campo, Gaël Roué, and Dolors Colomer
- 3969 **Instability of Foxp3 Expression Limits the Ability of Induced Regulatory T Cells to Mitigate Graft versus Host Disease**
Amy Beres, Richard Komorowski, Masahiko Mihara, and William R. Drobyski

3984 **Intratumoral Administration of TLR4 Agonist Absorbed into a Cellular Vector Improves Antitumor Responses**

Meghan B. Davis, David Vasquez-Dunddel, Juan Fu, Emilia Albesiano, Drew Pardoll, and Young J. Kim

3993 **Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth**

Guilherme Z. Rocha, Marília M. Dias, Eduardo R. Ropelle, Felipe Osório-Costa, Franco A. Rossato, Anibal E. Vercesi, Mario J.A. Saad, and José B.C. Carvalheira

4006 **Molecular Chemotherapy and Chemotherapy: A New Front against Late-Stage Hormone-Refractory Prostate Cancer**

Preetiner Pal Singh, Swapna Joshi, Pamela J. Russell, Nirupama D. Verma, Xiaochun Wang, and Aparajita Khatri

4019 **Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis**

Thomas Unterkircher, Silvia Cristofanon, Sri Hari Krishna Vellanki, Lisa Nonnenmacher, Georg Karpel-Massler, Christian Rainer Wirtz, Klaus-Michael Debatin, and Simone Fulda

4031 **Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families**

Tai W. Wong, Francis Y. Lee, Stuart Emanuel, Craig Fairchild, Joseph Fagnoli, Brian Fink, Ashvinikumar Gavai, Amy Hammell, Benjamin Henley, Christine Hilt, John T. Hunt, Bala Krishnan, Daniel Kukral, Anne Lewin, Harold Malone, Derek Norris, Simone Oppenheimer, Gregory Vite, and Chiang Yu

4042 **Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis**

Marion Zillhardt, Sun-Mi Park, Iris L. Romero, Kenjiro Sawada, Anthony Montag, Thomas Krausz, S. Diane Yamada, Marcus E. Peter, and Ernst Lengyel

IMAGING, DIAGNOSIS, PROGNOSIS

4052 **Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival**

Wei Dai, Jens M. Teodoridis, Constanze Zeller, Janet Graham, Jenny Hersey, James M. Flanagan, Euan Stronach, David W. Millan, Nadeem Siddiqui, Jim Paul, and Robert Brown

4063 **Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary**

Gauri R. Varadhachary, Yael Spector, James L. Abbruzzese, Shai Rosenwald, Huamin Wang, Ranit Aharonov, Heather R. Carlson, Dalia Cohen, Siddharth Karanth, Joanna Macinskas, Renato Lenzi, Ayelet Chajut, Tina B. Edmonston, and Martin N. Raber

CANCER THERAPY: CLINICAL

4071 **Sirolimus Therapy for Angiomyolipoma in Tuberos Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial**

D. Mark Davies, Petrus J. de Vries, Simon R. Johnson, Deborah L. McCartney, Jane A. Cox, Andreas L. Serra, Peter C. Watson, Christopher J. Howe, Tim Doyle, Kate Pointon, Justin J. Cross, Anne E. Tattersfield, J. Chris Kingswood, and Julian R. Sampson

4082 **Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis**

Mrinal M. Gounder, Robert A. Lefkowitz, Mary Louise Keohan, David R. D'Adamo, Meera Hameed, Cristina R. Antonescu, Samuel Singer, Katherine Stout, Linda Ahn, and Robert G. Maki


4091 **Treatment of Advanced Pancreatic Carcinoma with ⁹⁰Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial**

Seza A. Gulec, Steven J. Cohen, Kenneth L. Pennington, Lionel S. Zuckier, Ralph J. Hauke, Heather Horne, William A. Wegener, Nick Teoh, David V. Gold, Robert M. Sharkey, and David M. Goldenberg

4101	<p>CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans Rong Rong Huang, Jason Jalil, James S. Economou, Bartosz Chmielowski, Richard C. Koya, Stephen Mok, Hooman Sazegar, Elizabeth Seja, Arturo Villanueva, Jesus Gomez-Navarro, John A. Glaspy, Alistair J. Cochran, and Antoni Ribas</p>	4136	<p>T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab Björn Engelbrekt Wahlin, Christer Sundström, Harald Holte, Hans Hagberg, Martin Erlanson, Herman Nilsson-Ehle, Ola Lindén, Marie Nordström, Bjørn Østenstad, Christian H. Geisler, Peter de Nully Brown, Tuula Lehtinen, Martin Maisenhölder, Anne M. Tierens, Birgitta Sander, Birger Christensson, and Eva Kimby</p>
4110	<p>Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience Apostolia Maria Tsimberidou, Katherine Letourneau, Sijin Wen, Jennifer Wheler, David Hong, Aung Naing, Nancy G. Iskander, Cynthia Uehara, and Razelle Kurzrock <i>See commentary p. 3855</i></p>	4145	<p>A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer Enrique Casado, Victor Moreno García, Jose Javier Sánchez, Montserrat Blanco, Joan Maurel, Jaime Felíu, Carlos Fernández-Martos, Javier de Castro, Beatriz Castelo, Cristóbal Belda-Iniesta, María Sereno, Benito Sánchez-Llamas, Emilio Burgos, Miguel Ángel García-Cabezas, Noemí Manceño, Rosa Miquel, Damián García-Olmo, Manuel González-Barón, and Paloma Cejas</p>
4119	<p>The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma James J. Vredenburgh, Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon II, Jennifer Marcello, John P. Kirkpatrick, John H. Sampson, Leighann Bailey, Stevie Threatt, Allan H. Friedman, Darell D. Bigner, and Henry S. Friedman</p>	4155	<p>Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance Mariano Ponz-Sarvisé, Paul A. Nguewa, María J. Pajares, Jackeline Agorreta, María D. Lozano, Miriam Redrado, Ruben Pio, Carmen Behrens, Ignacio I. Wistuba, Carlos E. García-Franco, Jesús García-Foncillas, Luis M. Montuenga, Alfonso Calvo, and Ignacio Gil-Bazo</p>
PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE			
4125	<p>MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP Alvaro J. Alencar, Raquel Malumbres, Goldi A. Kozloski, Ranjana Advani, Neha Talreja, Shideh Chinichian, Javier Briones, Yasodha Natkunam, Laurie H. Sehn, Randy D. Gascoyne, Rob Tibshirani, and Izidore S. Lossos</p>	4167	<p>Absence of MMP2 Expression Correlates with Poor Clinical Outcomes in Rectal Cancer, and Is Distinct from MMP1-Related Outcomes in Colon Cancer John C.T. Wong, Simon K. Chan, David F. Schaeffer, Xavier Sagaert, Howard J. Lim, Hagen Kennecke, David A. Owen, Kwang W. Suh, Young-Bae Kim, and Isabella T. Tai</p>
		4177	<p>Progesterone Receptor Isoform-Specific Promoter Methylation: Association of PRA Promoter Methylation with Worse Outcome in Breast Cancer Patients Thushangi N. Pathiraja, Priya B. Shetty, Jaroslav Jelinek, Rong He, Ryan Hartmaier, Astrid L. Margossian, Susan G. Hilsenbeck, Jean-Pierre J. Issa, and Steffi Oesterreich</p>

ABOUT THE COVER

TLR4 agonist-formulated GVAX (TEGVAX) significantly increased cytolytic CD8 infiltration into the tumor microenvironment. CT26 tumor-bearing mice were treated with TEGVAX, which resulted in regression of tumor in 40% to 60% of the mice. Tumor-infiltrating CD8 cells (CD8-FITC, CD45-Cy3 conjugates) are shown in yellow and tumor is counterstained with DAPI (40x). For further details, please see Davis and coworkers on page 3984 in this issue.



Clinical Cancer Research

17 (12)

Clin Cancer Res 2011;17:3853-4186.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/17/12>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/17/12>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.